Working… Menu

A Clinical Trial of Apatinib Plus Docetaxel in Locally Advanced or Metastatic Gastric or GEJ Adenocarcinoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03071042
Recruitment Status : Unknown
Verified February 2017 by Hongming Pan, MD, Sir Run Run Shaw Hospital.
Recruitment status was:  Recruiting
First Posted : March 6, 2017
Last Update Posted : March 6, 2017
Jiangsu HengRui Medicine Co., Ltd.
Information provided by (Responsible Party):
Hongming Pan, MD, Sir Run Run Shaw Hospital

Brief Summary:
This study evaluated the tolerance, safety and efficacy of Apatinib plus Docetaxel as the second-line treatment in locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma).

Condition or disease Intervention/treatment Phase
Metastatic Gastric Adenocarcinoma Drug: Apatinib Drug: Docetaxel Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 12 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Dose Escalation Clinical Trial of Apatinib Tablets Plus Docetaxel as Second-line Treatment in Locally Advanced or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
Study Start Date : October 2015
Estimated Primary Completion Date : December 2017
Estimated Study Completion Date : June 2018

Resource links provided by the National Library of Medicine

Drug Information available for: Docetaxel

Arm Intervention/treatment
Experimental: Apatinib plus Docetaxel
Each subject will receive one dose of Apatinib in the whole cycle (21 days), during which single dose induced DLT and safety monitoring will be performed. If the initial dose is well tolerated, next cycle the subject will receive more Apatinib as respectively. This study will enroll in 4 cohorts of Apatinib; cohort 1 at the dose of 425mg Apatinib, which followed by cohort 2(500mg), cohort 3(675mg) and cohort 4(750mg).
Drug: Apatinib
Apatinib Mesylate Tablets 425mg (500mg,675mg or 750mg) po. qd continuous;
Other Name: YN968D1,(AiTan®)

Drug: Docetaxel
Docetaxel 60mg/m2 ivgtt day 1, q21d Combined use of Docetaxel and Apatinib
Other Name: Aisu®

Primary Outcome Measures :
  1. Tolerance profile of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: At least 4 weeks ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patient has to voluntarily join the study and sign the Informed Consent Form for the study;
  2. Age: ≥18 years old;
  3. Locally advanced or metastatic gastric cancer (including Gastroesophageal junction (GEJ) Adenocarcinoma ) patients confirmed by radiologic imaging or endoscopy tests, who had failed in first-line treatments;

    • First-line treatment should be 5-Fu combined with platinum based regimen;
    • Adjuvant/neoadjuvant chemotherapy should be defined as the first-line treatment, if recurrence happened within 6 months after completion of 5-Fu and platinum based adjuvant/ neoadjuvant chemotherapy;
  4. Adjuvant/neoadjuvant chemotherapy history is allowed, if first-line treatment is applied more than 6 months later than prior treatments;
  5. Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests, and other study procedure;
  6. ECOG Performance Status ≤1;
  7. Life expectancy shouldn't less than 16 weeks, since the first medicine application time;
  8. Major organ function has to meet the following criteria (within 28 days before treatment):

    • HB ≥9.0 g/dL
    • ANC ≥1.5X109/L
    • PLT ≥100x109/L
    • Bilirubin ≤1.5 times the upper limit of normal (ULN)
    • ALT (SGOT) and AST (SGPT) ≤2.5 × ULN, unless liver metastases; if any, the ALT and AST≤5 × ULN
    • Serum Cr ≤ 1.5 x ULN
  9. Patients must have at least one assessable lesion (including measurable and/or immeasurable) by radiological imagine (CT/MRI);
  10. Pregnancy test (serum or urine) has to be performed for woman of childbearing age within 28 days before enrollment and the test result must be negative. Or menopause women, defined as follow:

    • ≥1 year no menstruation, after abort exogenous hormone treatment
    • Serum LH and FSH meet menopause criteria
    • More than 1 year no menstruation for ovarian function failure induced by radiation therapy.
    • More than 1 year no menstruation for menopause induced by chemotherapy
    • Surgical sterilization accepted (hysterectomy or ovariectomy)

Exclusion Criteria:

  1. Involved in another on-going clinical trials;
  2. Accept more than one chemotherapy previously in advanced gastric cancer (except more than 6 months from adjuvant/neoadjuvant treatment);
  3. Prior taxane treatment (including Paclitaxel and Docetaxel);
  4. Prior VEGFR inhibitor treatment (including Sorafenib and Sunitinib);
  5. History of another malignancy within the last five years except cured nonmelanoma Skin cancer and carcinoma in situ of uterine cervix;
  6. Any factors that influence the usage of oral administration;
  7. History of the investigational agent treatment in 14 day prior to enroll in study (longer time period may be required which depends on drug characteristic);
  8. Accept any chemotherapy and radiotherapy (excluding Palliative radiotherapy) in 3 weeks prior to study (longer time period may be required which depends on drug characteristic);
  9. Poor-controlled arterial hypertension (systolic blood pressure> 140 mmHg and diastolic blood pressure > 90 mm Hg) despite standard medical management; Coronary heart disease greater than Class I; I-level arrhythmia (including QT interval prolongation, for man ≥ 450 ms, for woman ≥ 470 ms) together with Class I cardiac dysfunction; Patients with positive urinary protein;
  10. Poor-controlled adverse events (excluding Alopecia) induced by tumor therapy (>class 1 CTCAE);
  11. History of intestinal obstruction or more than class 3 or 4 (CTCAE) gastrointestinal bleeding in 4 weeks prior to enroll in study;
  12. Abnormal Coagulation (INR>1.5、APTT>1.5 UNL), with tendency of bleed;
  13. Clinical evidence in central nervous system (CNS) and poor-controlled CNS metastasis (No necessary to confirm negative CNS metastasis by CT/MRI);
  14. Surgery within 2 weeks prior to enroll in study;
  15. History of significant and poor-controlled diseases or infection, in the opinion of investigators, may impact the safety of the patients of the study;
  16. Known history of human immunodeficiency, e.g. HIV positive;
  17. Known or suspected allergy to the investigational agent or any agent given in association with this trial;
  18. Pregnant or lactating patients.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03071042

Layout table for location contacts
Contact: Hongming Pan, MD +86-13605716662

Layout table for location information
China, Zhejiang
Sir Run Run Shaw Hospital Recruiting
Hangzhou, Zhejiang, China, 310016
Contact: Pan Hongming, MD    +86-13605716662      
Sponsors and Collaborators
Sir Run Run Shaw Hospital
Jiangsu HengRui Medicine Co., Ltd.
Layout table for investigator information
Study Chair: Hongming Pan, MD The Affiliated Sir Run Run Shaw Hospital

Layout table for additonal information
Responsible Party: Hongming Pan, MD, Principal Investgator, Sir Run Run Shaw Hospital Identifier: NCT03071042     History of Changes
Other Study ID Numbers: Ahead-G306
First Posted: March 6, 2017    Key Record Dates
Last Update Posted: March 6, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Undecided
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Protein Kinase Inhibitors
Enzyme Inhibitors